Skip To Content

Support the Forward

Funded by readers like you DonateSubscribe
Fast Forward

Sackler Family’s OxyContin Firm To Face Suit From Native Americans

The OxyContin manufacturer Purdue Pharma, along with two dozen other opioid makers, are facing a lawsuit brought by three Native American tribes in the Dakotas, claiming that the firms hid the drug’s risk.

Purdue is privately owned by the Sackler family, who are Jewish. (After the publication of this brief, a representative for one branch of the family, the descendants of Arthur M. Sackler, contacted the Forward to note that their branch sold their share of the firm in the 1980s and has never benefited from the sale of OxyContin.)

According to the Associated Press, the three tribes are asking for monetary damages and a fund to pay for addiction treatment.

“This epidemic has overwhelmed our public-health and law-enforcement services, drained resources for addiction therapy, and sent the cost of caring for children of opioid-addicted parents skyrocketing,” Brendan Johnson, a lawyer representing the tribes, told the AP.

Native American populations in South Dakota have been disproportionately affected by the opioid crisis.

Contact Josh Nathan-Kazis at [email protected] or on Twitter, @joshnathankazis.


Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.